AU2007293302A1 - Biomarkers for assessing liver function - Google Patents

Biomarkers for assessing liver function Download PDF

Info

Publication number
AU2007293302A1
AU2007293302A1 AU2007293302A AU2007293302A AU2007293302A1 AU 2007293302 A1 AU2007293302 A1 AU 2007293302A1 AU 2007293302 A AU2007293302 A AU 2007293302A AU 2007293302 A AU2007293302 A AU 2007293302A AU 2007293302 A1 AU2007293302 A1 AU 2007293302A1
Authority
AU
Australia
Prior art keywords
individual
liver
patients
liver disease
adma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007293302A
Other languages
English (en)
Inventor
Nathan Davies
Rajiv Jalan
Rajeshwar P Mookerjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of AU2007293302A1 publication Critical patent/AU2007293302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2007293302A 2006-09-07 2007-09-07 Biomarkers for assessing liver function Abandoned AU2007293302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0617581.4 2006-09-07
GBGB0617581.4A GB0617581D0 (en) 2006-09-07 2006-09-07 Biomarkers for assessing liver function
PCT/GB2007/003362 WO2008029145A1 (en) 2006-09-07 2007-09-07 Biqmarkers for assessing liver function

Publications (1)

Publication Number Publication Date
AU2007293302A1 true AU2007293302A1 (en) 2008-03-13

Family

ID=37232490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007293302A Abandoned AU2007293302A1 (en) 2006-09-07 2007-09-07 Biomarkers for assessing liver function

Country Status (16)

Country Link
US (1) US8455220B2 (enExample)
EP (1) EP2059817B1 (enExample)
JP (1) JP4949473B2 (enExample)
KR (1) KR20090083335A (enExample)
AT (1) ATE488772T1 (enExample)
AU (1) AU2007293302A1 (enExample)
CA (1) CA2662597A1 (enExample)
DE (1) DE602007010644D1 (enExample)
EA (1) EA200970256A1 (enExample)
ES (1) ES2353835T3 (enExample)
GB (1) GB0617581D0 (enExample)
IL (1) IL197271A0 (enExample)
MX (1) MX2009002378A (enExample)
NO (1) NO20090993L (enExample)
WO (1) WO2008029145A1 (enExample)
ZA (1) ZA200901432B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2715346B1 (en) 2011-05-31 2020-07-15 The Regents of the University of Colorado, A Body Corporate Method for assessment of hepatic function and portal blood flow
CA2891281C (en) * 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
WO2014190170A1 (en) * 2013-05-22 2014-11-27 The Regents Of The University Of California Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment
CN107206049B (zh) * 2014-10-24 2021-12-07 马林克罗特医疗产品知识产权公司 治疗患1型肝肾综合征的患者的方法
CN105181692A (zh) * 2015-09-30 2015-12-23 山东博科生物产业有限公司 一种缺血修饰白蛋白比色法检测试剂盒
WO2017081073A1 (en) * 2015-11-10 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients with decompensated alcoholic cirrhosis
WO2020104458A1 (en) * 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for detecting liver dysfunction in a subject
CN121331222B (zh) * 2025-12-15 2026-03-10 北京大学 基于蛋白质组的慢性肝脏疾病发病预测的蛋白组合、预测模型及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2340397A (en) 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
AU2002352959B2 (en) * 2001-11-26 2008-04-10 Ischemia Technologies, Inc. Electrochemical detection of ischemia
WO2004012686A2 (en) * 2002-08-06 2004-02-12 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
AU2003290784A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for detecting asymmetric dimethylarginine in a biological sample
WO2005039598A1 (en) 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern

Also Published As

Publication number Publication date
EA200970256A1 (ru) 2009-08-28
US8455220B2 (en) 2013-06-04
EP2059817A1 (en) 2009-05-20
ATE488772T1 (de) 2010-12-15
US20090280519A1 (en) 2009-11-12
WO2008029145A1 (en) 2008-03-13
JP2010502979A (ja) 2010-01-28
CA2662597A1 (en) 2008-03-13
NO20090993L (no) 2009-04-03
ZA200901432B (en) 2010-06-30
GB0617581D0 (en) 2006-10-18
MX2009002378A (es) 2009-03-20
ES2353835T3 (es) 2011-03-07
DE602007010644D1 (de) 2010-12-30
EP2059817B1 (en) 2010-11-17
KR20090083335A (ko) 2009-08-03
JP4949473B2 (ja) 2012-06-06
IL197271A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
EP2059817B1 (en) Biomarkers for assessing liver function
Mookerjee et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis
Parikh et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery
JP5054525B2 (ja) 腎疾患および腎損傷の早期発見のための方法
Premaratne et al. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate
EP2131200A1 (en) A marker for graft failure and mortality
US7977110B2 (en) Method for distinguishing between kidney dysfunctions
EP2506016B1 (en) Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker
Aydin et al. Adropin as a potential marker of enzyme-positive acute coronary syndrome
WO2012116074A1 (en) Biomarkers of insulin sensitivity
Su et al. The value of serial serum cell adhesion molecules in predicting acute kidney injury after severe sepsis in adults
CN111065927B (zh) 作为危重患者的治疗监测标记物的pro-adm
Leśnik et al. Measurement of serum levels of 5 amino acids and dimethylamine using liquid chromatography-tandem mass spectrometry in patients without septic associated acute kidney injury and with septic associated acute kidney injury requiring continuous renal replacement therapy
WO2019242751A1 (en) Small molecular biomarkers for nephropathy and applications thereof
CN114755313A (zh) 包含尿液nad+代谢物的急性肾损伤标志物
US20120028881A1 (en) Methods and reagents for diagnosing atheroma
WO2022221264A1 (en) Methods and compositions for analysis of acute kidney injury
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
Neumann et al. NephroPOC–Proenkephalin A 119-159 predicts acute kidney injury and 28-day mortality in patients with suspected organ dysfunction in the emergency department (ED): secondary analysis from the prospective observational LifePOC study
Reddy et al. Acute kidney injury biomarkers
BR102024010366A2 (pt) Método in vitro, painel de biomarcadores, kit para predição, rastreamento, monitoramento e/ou diagnóstico de doença renal diabética e método de tratamento
AU2011253624B2 (en) Method for the early detection of renal disease and injury
JP5020239B6 (ja) インスリン抵抗性病態を示す疾患の検出方法
JP5020239B2 (ja) インスリン抵抗性病態を示す疾患の検出方法
TW202319747A (zh) 用以預斷肌少症患者存活率的方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ BIOMARKERS FOR ASSESSING LIVER FUNCTION

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period